Summary
Signal counts
Assets tracked: 2
Watchlist assets: 1
Registry stop assets: 0
Sponsor overview
Astellas Pharma Global Development, .
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT07488676 | https://clinicaltrials.gov/study/NCT03505320
Assets
Linked programs
- ASP546C: Low Signal (1/5)
- zolbetuximab: Watchlist Signal (2/5)